NICE | March 2020 |COVID-19 rapid guideline: delivery of systemic anticancer treatments
NICE guideline [NG161]
The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.
On 3 April 2020, NICE added 2 recommendations on when to offer and continue systemic anticancer treatment for patients with COVID-19. NICE also amended the table on prioritising treatments in line with new advice from NHS England.
This guideline is for:
- health and care practitioners
- health and care staff involved in planning and delivering services
Further information availlable from NICE
NICE has also produced a COVID-19 rapid guideline on delivery of radiotherapy.